IMC Logo.jpg
IMM-124E – Demonstrates Antiviral T-Cell Immunity
October 08, 2021 06:00 ET | Immuron Limited
Key Points International Patent Filed Publication from the Hebrew University - Hadassah Medical Center Entitled: Augmented antiviral T cell immunity by oral administration of IMM-124E in preclinical...
IMC Logo.jpg
IMM124E – May offer a New modality for Inhibition of SARS-CoV-2
May 13, 2021 06:00 ET | Immuron Limited
Key Points Monash University Research Update on SARS-CoV-2 programBiomedicine Discovery Institute initiates program to isolate and identify the inhibitory molecule/s in IMM-124E Appointment of Chief...
IMC Logo.jpg
Immuron Travelers’ Diarrhea Market Update
October 12, 2020 06:00 ET | Immuron Limited
Key Points Immuron’s IMM-124E IND Program recommencesUniformed Services University to recommence planned Travelers’ Diarrhea clinical studyCOVID-19 - Consultancy Agreement with Infectious Disease...
IMC Logo.jpg
US Department of Defense Reports Final Results from Travelan® Shigellosis Challenge Study
June 12, 2019 07:00 ET | Immuron Limited
Key Highlights: Travelan® shigellosis challenge studies in non-human primates successfully completedTravelan® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan® treated animals...
IMC Logo.jpg
Immuron sales surge by 66% in the Third Quarter of FY19
April 15, 2019 09:00 ET | Immuron Limited
Key Highlights: Immuron achieved 66% YoY growth in worldwide sales for the third quarter of FY19, ending March 31, 2019.In Australia Q3 sales of Travelan® surged ahead, growing 73% YoY.In the US Q3...
IMC Logo.jpg
Immuron Aims to Secure FDA Approval for IMM-124E to Prevent Travelers’ Diarrhea
April 11, 2019 09:00 ET | Immuron Limited
Key Points Immuron to develop U.S. registration dossier for IMM-124E for Travelers’ DiarrheaCompany anticipates significant inflection in sales with successful FDA registration of IMM-124ECompany to...
IMC Logo.jpg
Immuron Reports Significant Alleviation of Colitis Symptoms in Preclinical Program
May 07, 2018 21:43 ET | Immuron Limited
MELBOURNE, Australia, May 07, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing orally...
IMC Logo.jpg
Immuron to Receive $2.16M R&D Tax Concession Refund
January 24, 2018 09:30 ET | Immuron Limited
Melbourne, Australia, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) is pleased to announce that under the Australian Government’s Research and Development...
IMC Logo.jpg
Immuron Granted US Patent for NASH Treatment
November 15, 2017 09:00 ET | Immuron Limited
MELBOURNE, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercialising oral...
IMC Logo.jpg
Immuron Successfully Completes NASH Phase II Clinical Study Milestone
November 09, 2017 09:00 ET | Immuron Limited
MELBOURNE, Australia, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercialising oral...